Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens

Clinical and Vaccine Immunology

Volumn 18, Issue 4, 2011, Pages 595-603

  Stenger, Rachel M ^a   Smits, Mieke ^a   Kuipers, Betsy ^a   Kessen, Sabine F M ^a   Boog, Claire J P ^a   Van Els, Cécile A C M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS ANTIBODY; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MOUSE; MULTIPLEX IMMUNOASSAY; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TETANUS; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; SENSITIVITY AND SPECIFICITY;

EID: 79954520208     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00061-10     Document Type: Article

References (51)

1. Aase, A., et al. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536.
2. Arigita, C., et al. 2003. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 21:950-960. (Pubitemid 36126430)
3. Banus, S., et al. 2008. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol. 9:21.
4. Bennion, B. J., and V. Daggett. 2003. The molecular basis for the chemical denaturation of proteins by urea. Proc. Natl. Acad. Sci. U. S. A. 100:5142-5147.
5. Borgers, H., et al. 2010. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin. Immunol. 134:198-205.
6. Borrow, R., N. Andrews, D. Goldblatt, and E. Miller. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568-1573.
7. Corbel, M. J., et al. 2008. WHO Working Group on Revision of the Manual of Laboratory Methods for Testing DTP Vaccines - report of two meetings held on 20-21 July 2006 and 28-30 March 2007, Geneva, Switzerland. Vaccine 26:1913-1921.
8. Delgado, M. F., et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41.
9. Denoel, P. A., D. Goldblatt, I. de Vleeschauwer, J. M. Jacquet, M. E. Pichichero, and J. T. Poolman. 2007. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/ Hib combination vaccines. Clin. Vaccine Immunol. 14:1362-1369.
10. de Voer, R. M., R. M. Schepp, F. G. Versteegh, F. R. van der Klis, and G. A. Berbers. 2009. Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin. Vaccine Immunol. 16:433-436.
11. de Voer, R. M., et al. 2008. Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides. Clin. Vaccine Immunol. 15:1188-1193.
12. Eskola, J., et al. 1999. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354:2063-2068.
13. European Pharmacopoeia Commission. 2005. European pharmacopoeia 5.0. Assay of pertussis vaccine (acellular); document 01/2005:20716. European Directorate for the Quality of Medicines, Strasburg, France.
14. Fenoy, S., M. Rodero, E. Pons, C. Aguila, and C. Cuellar. 2008. Follow-up of antibody avidity in BALB/c mice infected with Toxocara canis. Parasitology 135:725-733. (Pubitemid 351733165)
15. Gaines Das, R., D. Xing, P. Rigsby, P. Newland, and M. Corbel. 2001. International collaborative study: evaluation of proposed International Reference Reagent of pertussis antiserum (mouse) 97/642. Biologicals 29:137-148. (Pubitemid 32977042)
16. Geurtsen, J., et al. 2008. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses. Vaccine 26:899-906.
17. Gylca, R., et al. 2000. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 19:825-833.
18. Hendrikx, L. H., G. A. Berbers, R. H. Veenhoven, E. A. Sanders, and A. M. Buisman. 2009. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 27:6530-6536.
19. Hijnen, M., et al. 2004. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect. Immun. 72:3716-3723.
20. Hua, L., R. Zhou, D. Thirumalai, and B. J. Berne. 2008. Urea denaturation by stronger dispersion interactions with proteins than water implies a 2-stage unfolding. Proc. Natl. Acad. Sci. U. S. A. 105:16928-16933.
21. Huber, V. C., et al. 2006. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 13:981-990.
22. Iihara, H., et al. 2007. Rapid multiplex immunofluorescent assay to detect antibodies against Burkholderia pseudomallei and taxonomically closely related nonfermenters. Jpn. J. Infect. Dis. 60:230-234.
23. Jones, L. P., et al. 2002. Multiplex assay for detection of strain-specific antibodies against the two variable regions of the G protein of respiratory syncytial virus. Clin. Diagn. Lab. Immunol. 9:633-638.
24. Lal, G., P. Balmer, H. Joseph, M. Dawson, and R. Borrow. 2004. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin. Diagn. Lab. Immunol. 11:272-279.
25. Lal, G., et al. 2005. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J. Immunol. Methods 296:135-147. (Pubitemid 40174747)
26. Locht, C., P. Bertin, F. D. Menozzi, and G. Renauld. 1993. The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp. Mol. Microbiol. 9:653-660.
27. Lottenbach, K. R., et al. 1999. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67:4935-4938.
28. Luijkx, T. A., J. A. van Gaans-van den Brink, H. H. van Dijken, G. P. van Den Dobbelsteen, and C. A. van Els. 2008. Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model. Clin. Vaccine Immunol. 15:1598-1605.
29. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the absence of detectable circulating anti-body: implications for long-term immunity in children. J. Infect. Dis. 181:2087-2091.
30. Mason, P. E., G. W. Neilson, C. E. Dempsey, A. C. Barnes, and J. M. Cruickshank. 2003. The hydration structure of guanidinium and thiocyanate ions: implications for protein stability in aqueous solution. Proc. Natl. Acad. Sci. U. S. A. 100:4557-4561.
31. Mielcarek, N., et al. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2:e65.
32. Mills, K. H. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:655-677. (Pubitemid 32607761)
33. Mills, K. H., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
34. Pickering, J. W., M. T. Larson, T. B. Martins, S. S. Copple, and H. R. Hill. 2010. Elimination of false-positive results in a Luminex assay for pneumococcal antibodies. Clin. Vaccine Immunol. 17:185-189.
35. Pickering, J. W., et al. 2002. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am. J. Clin. Pathol. 117:589-596.
36. Plotkin, S. A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-409.
37. Polack, F. P., S. J. Hoffman, G. Crujeiras, and D. E. Griffin. 2003. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9:1209-1213.
38. Poolman, J. T., B. Kuipers, M. L. Vogel, H. J. Hamstra, and J. Nagel. 1990. Description of a hybridoma bank towards Bordetella pertussis toxin and surface antigens. Microb. Pathog. 8:377-382.
39. Prince, H. E., M. Lape-Nixon, and J. Matud. 2006. Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies. Clin. Vaccine Immunol. 13:266-270.
40. Pullen, G. R., M. G. Fitzgerald, and C. S. Hosking. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86:83-87.
41. Reder, S., M. Riffelmann, C. Becker, and C. H. Wirsing von Konig. 2008. Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay. Clin. Vaccine Immunol. 15:744-749.
42. Robinson, A., A. R. Gorringe, S. G. Funnell, and M. Fernandez. 1989. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 7:321-324. (Pubitemid 19215712)
43. Sato, Y., J. L. Cowell, H. Sato, D. G. Burstyn, and C. R. Manclark. 1983. Separation and purification of the hemagglutinins from Bordetella pertussis. Infect. Immun. 41:313-320.
44. Sekura, R. D., F. Fish, C. R. Manclark, B. Meade, and Y. L. Zhang. 1983. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J. Biol. Chem. 258:14647-14651.
45. Siegrist, C. A., et al. 2004. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23:615-622.
46. Skerry, C. M., et al. 2009. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin. Vaccine Immunol. 16:1344-1351.
47. + T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect. Immun. 77:896-903.
48. Thalen, M., A. van der Ark, J. van den Ijssel, I. van Straaten, D. Jansen, C. Beuvery, D. Martens, and J. Tramper. 2008. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine 26:653-663.
49. Underwood, J. R., M. Chivers, T. T. Dang, and P. V. Licciardi. 2009. Stimulation of tetanus toxoid-specific immune responses by a traditional Chinese herbal medicine. Vaccine 27:6634-6641.
50. van Gageldonk, P. G., F. G. van Schaijk, F. R. van der Klis, and G. A. Berbers. 2008. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J. Immunol. Methods 335:79-89.
51. Westdijk, J., J. van den Ijssel, M. Thalen, C. Beuvery, and W. Jiskoot. 1997. Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA. J. Immunoassay. 18:267-284. (Pubitemid 27319047)